Skip to main content

Table 2 Baseline characteristics and medications of the participants

From: Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes

 

Control (n = 28)

Omarigliptin (n = 56)

p value

Age (years)

59.17 ± 7.85

59.00 ± 7.33

0.638

Male/(female)

21 (7)

40 (16)

0.8

Baseline medication

 Sitagliptin

19

40

0.802

 Linagliptin

9

16

0.802

 Sulfonylureas

5

11

1

 Metformin

7

14

1

 α-GI

4

6

0.7248

 ARB

9

18

1

 CCB

6

14

0.7913

 Statins

9

19

1

 Fibrates

5

11

1

  1. Data were expressed as mean ± standard deviation
  2. α-GI, α-glicosidase inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us